����ӰԺ

SOMERSET, N.J. – March 6, 2023 — ����ӰԺ. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Sridhar Krishnan, to the newly created position of Vice President, The ����ӰԺ Way, where he will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence, enabling growth. He will also serve on the Executive Leadership Team, reporting directly to ����ӰԺ’s President & Chief Executive Officer, Alessandro Maselli.

The ����ӰԺ Way is a company-wide system of continuous improvement with clear standards to enable more predictable and efficient processes. Mr. Krishnan will work alongside senior executives across the company’s business segments, and more than 50 global facilities, to implement this strategy.

Mr. Krishnan returns to ����ӰԺ having spent the previous four years in a number of roles within the pharmaceutical industry, most recently as SVP, Head of Operations, for Jubilant Pharma. He has over 20 years of operational leadership experience within the CDMO space, including as Vice President of Global Operations, and subsequently as Vice President, Global Procurement & Business Analytics at ����ӰԺ. He holds a bachelor’s degree in mechanical engineering and is a Six Sigma Master Black Belt.

Commenting on the appointment, Alessandro Maselli said, “Sridhar brings considerable operational leadership and Lean expertise, as well as a proven track record driving enterprise-wide business transformations and operational performance. We welcome him back to ����ӰԺ, in a role where he will provide the key strategic focus necessary to not only establish new standards of excellence at ����ӰԺ, but within the pharmaceutical industry.”

NOTES FOR EDITORS

ABOUT CATALENT

����ӰԺ. (NYSE: CTLT), an S&P 500^® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, ����ӰԺ is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. ����ӰԺ helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually.

����ӰԺ’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information .

More products. Better treatments. Reliably supplied.™

FORWARD LOOKING STATEMENTS

This release contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe ����ӰԺ’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from ����ӰԺ’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic or any global health developments on ����ӰԺ’s or its customers’ or suppliers’ businesses; participation in a highly competitive market and increased competition that may adversely affect ����ӰԺ’s business; demand for its offerings, which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect ����ӰԺ’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on ����ӰԺ’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to ����ӰԺ’s operations, including risks from rising inflation, disruptions to global supply chains, or from the Ukrainian-Russian war; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products ����ӰԺ manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to ����ӰԺ’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition or other transaction that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund ����ӰԺ’s existing pension plans; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in ����ӰԺ’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed August 29, 2022. All forward-looking statements speak only as of the date of this release or as of the date they are made, and ����ӰԺ does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.